Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 397-409 , December 2000

A comparison of treatment results for recurrent malignant gliomas

References 

    REFERENCES
  1. Nieder C, Nestle U. A review of current and future treatment strategies for malignant astrocytomas in adults. Strahlenther Onkol. 2000;176:251–258
  2. Halperin EC, Berger PC, Bullard DE. The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol Biol Phys. 1988;15:505–509
  3. Gaspar LE, Fisher BJ, McDonald D. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local therapy. Int J Radiat Oncol Biol Phys. 1992;24:55–57
  4. Hochberg FH, Pruit A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907–911
  5. Sneed PK, Gutin PH, Larson DA. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys. 1994;29:719–727
  6. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1405–1408
  7. Lee SW, Herbort K, Martel MK, Marsh LH, Gebarski SS, Radany EH. Patterns of failure following 3-D conformal dose escalation radiotherapy for high grade astrocytomas – a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1996;36:159–164
  8. Loeffler JS, Alexander E, Hochberg FH. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys. 1990;19:1455–1462
  9. Bauman GS, Fisher BJ, Cairncross JG, McDonald D. Bihemispheric malignant glioma: one size does not fit all. J Neurooncol. 1998;38:83–89
  10. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytomas: results of a systematic review of 1415 patients. Anticancer Res. 1998;18:1303–1311
  11. Djubegovic B, Loughran TP, Hornung CA. The quality of medical evidence in Hematology-Oncology. Am J Med. 1999;106:198–205
  12. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users guide to the medical literature. IX. A method for grading health care recommendations. JAMA. 1995;274:1880–1884
  13. Brem H, Piantadosi S, Burger PC. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008–1012
  14. Bleehen NM, Freedman LS, Stenning SP. A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Int J Radiat Oncol Biol Phys. 1989;16:1077–1081
  15. Boiardi A, Silvani A, Milanesi I, Broggi G, Fariselli L. Efficacy of “8-drugs-in-one-day” combination in treatment of recurrent GBM patients. J Neurooncol. 1992;12:153–158
  16. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosurea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery. 1999;45:17–22
  17. Muehling M, Krage S, Hussein S, Samii M. Indication for repeat surgery of glioblastoma: influence of progress of disease. Front Radiat Ther Oncol. 1999;33:192–201
  18. Harsh GR, Levin VA, Gutin PH, Seager M, Silver P, Wison CB. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987;21:615–621
  19. Young B, Oldfiel EH, Markesberry WR. Re-operation for glioblastoma. J Neurosurg. 1981;55:917–921
  20. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery. 1994;35:378–388
  21. Barker FG, Chang SM, Gutin PH. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998;42:709–720
  22. Ammirati M, Galicich JC, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21:607–614
  23. Sipos L, Afra D. Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir. 1997;139:99–104
  24. Poisson M, Pereon Y, Chiras J, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with carboplatin. J Neurooncol. 1991;10:139–144
  25. Ameri A, Poisson M, Chauveinc L, Chen QM, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol. 1997;32:155–160
  26. Sanson M, Ameri A, Monjour A. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer. 1996;32A:2229–2235
  27. Van den Bent MJ, Schellens JH, Vecht CJ. Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. Eur J Cancer. 1998;34:1570–1574
  28. Hildebrand J, De Witte O, Sahmoud T. Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine – a phase-II study. J Neurooncol. 1998;37:155–160
  29. Gregor A, Lind M, Newman H. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high-grade glioma. J Neurooncol. 1999;44:137–145
  30. Galanis E, Buckner JC, Burch PA. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol. 1998;16:2953–2958
  31. Friedman HS, Petros WP, Friedman AH. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516–1525
  32. Wong ET, Hess KR, Gleason MJ. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572–2578
  33. Chamberlain MC, Kormanik P. Salvage chemotherapy with taxol for recurrent anaplastic astrocytomas. J Neurooncol. 1999;43:71–78
  34. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000;18:1481–1491
  35. Brandes AA, Scelzi E, Zampieri P. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol. 1997;20:364–367
  36. Bower M, Newlands ES, Bleehen NM. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40:484–488
  37. Paulsen F, Hoffmann W, Becker G. Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J Cancer Res Clin Oncol. 1999;125:411–418
  38. Newlands ES, O’Reilly SM, Glaser MG. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996;32A:2236–2241
  39. Stein ME, Kuten A, Drumea K, Goldsher D, Tzuk-Shina Z. Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure. J Surg Oncol. 1999;71:167–170
  40. Van den Bent MJ, Pronk L, Sillevis Smitt PA, Vecht CJ, Eskens FA, Verweij J. Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J Neurooncol. 1999;44:59–64
  41. Brandes AA, Ermani M, Turazzi S. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol. 1999;17:645–650
  42. Clarke K, Basser RL, Underhill C. KRN8602 (MX2-Hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. J Clin Oncol. 1999;17:2579–2584
  43. Chamberlain MC, Kormanik P. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol. 1995;13:2066–2071
  44. Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WK. All-trans -retinoic acid: a phase II RTOG study in patients with recurrent malignant astrocytoma. J Neurooncol. 1997;34:193–200
  45. McDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280
  46. Nieder C, Nestle U, Niewald M, Walter K, Schnabel K. Hyperfractionated reirradiation for malignant glioma. Front Radiat Ther Oncol. 1999;33:150–157
  47. Van Kampen M, Engenhart-Cabillic R, Debus J, Fuss M, Rhein B, Wannenmacher M. The value of radiosurgery for recurrent glioblastoma multiforme [German]. Strahlenther Onkol. 1998;174:19–24
  48. Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M. Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int J Radiat Oncol Biol Phys. 1998;40:661–666
  49. Kim HK, Thornton AF, Greenberg HS, Page MA, Junck L, Sandler HM. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am J Clin Oncol. 1997;20:358–363
  50. Hayat K, Jones B, Bisbrown G, Baria K, Pigott T. Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy. Clin Oncol (R Coll Radiol). 1997;9:158–163
  51. Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovo MG. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;43:789–793
  52. Sheperd SF, Laing RW, Cosgrove VP. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393–398
  53. Hudes RS, Corn BW, Werner-Wasik M. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:293–298
  54. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW. Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol. 1997;20:226–229
  55. Shaw E, Scott C, Souhami L. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases. Int J Radiat Oncol Biol Phys. 1996;34:647–654
  56. Chamberlain MC, Barba D, Kormanik P, Shea WM. Stereotactic radiosurgery for recurrent gliomas. Cancer. 1994;74:1342–1347
  57. Shrieve DC, Alexander E, Wen PY. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36:275–284
  58. Gaspar LE, Zamorano LJ, Shamsa F, Fontanesi J, Ezzell GE, Yakar DA. Permanent 125-iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 1999;43:977–982
  59. Sneed PK, Gutin PH, Stauffer PR. Thermoradiotherapy of recurrent malignant brain tumors. Int J Radiat Oncol Biol Phys. 1992;23:853–861
  60. Shand N, Weber F, Mariani L. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum Gene Ther. 1999;10:2325–2335
  61. Klatzmann D, Valery CA, Bensimon G. A phase I/II study of herpes simplex virus type 1 thymidine kinase suicide gene therapy for recurrent glioblastoma. Hum Gene Ther. 1998;9:2595–2604
  62. Fine HA, Figg WD, Jaeckle K. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin O ncol. 2000;18:708–715

PII: S0305-7372(00)90191-9

doi: 10.1053/ctrv.2000.0191

Cancer Treatment Reviews
Volume 26, Issue 6 , Pages 397-409 , December 2000

Article Tools